CONDUCT OF THE RESEARCH PROJECT Sample Clauses

CONDUCT OF THE RESEARCH PROJECT. The parties shall use all reasonable endeavours to carry out the Research Project to a high standard. <Lead institution> shall be responsible for obtaining all necessary ethical, administrative and governmental approvals required to conduct the Research Project as set out in Item 1 of Schedule 2. Austin Health shall supply all personnel, equipment, materials and other things necessary to perform the Research Project as expressed in Item 3 of Schedule 2. Austin Health shall co-operate with Collaborator and shall not interfere with or obstruct the proper performance of the Research Project.
Sample 1Sample 2
AutoNDA by SimpleDocs
CONDUCT OF THE RESEARCH PROJECT. The parties shall use all reasonable endeavours to carry out the Research Project to a high standard. Austin Health shall be responsible for obtaining all necessary ethical, administrative and governmental approvals required to conduct the Research Project as set out in Item 1 of Schedule 2. Austin Health shall supply all personnel, equipment, materials and other things necessary to perform the Research Project as expressed in Item 3 of Schedule 2. Austin Health shall co-operate with Collaborator and shall not interfere with or obstruct the proper performance of the Research Project.
Sample 1Sample 2
CONDUCT OF THE RESEARCH PROJECT. Each of the Research Institution and the Researcher will use, or cause to be used, reasonable scientific efforts to conduct the Research Project in accordance with Appendix B. If at any time the Research Institution or the Researcher makes a good faith determination that (A) the Research Project cannot be conducted substantially in accordance with Appendix B or the Budget (as defined in Section 3(a) of this Agreement) or (B) continued conduct of the Research Project in accordance with Appendix B is unlikely to yield scientifically valid or useful results, the Research Institution shall promptly give notice (a "Change of Circumstances Notice") to the Foundation.
Sample 1Sample 2
CONDUCT OF THE RESEARCH PROJECT. 3.1 [insert short form name] agrees to conduct the Research Project in accordance with this Agreement. 3.2 [insert short form name] shall use all reasonable endeavours to carry out the Research Project to a high standard and follow the Australian Code for the Responsible Conduct of Research (xxxxx://xxxxx.xxx.xx/about-us/publications/australian-code-responsible-conduct-research-2018) and the National Statement on Ethical Conduct in Human Research (xxxxx://xxxxx.xxx.xx/about-us/publications/national-statement-ethical-conduct-human-research-2007-updated-2018). 3.3 [insert short form name] must ensure that all necessary ethical, administrative and governmental approvals relating to the Research Project are in place before commencing the Research Project and provide these approvals to the NDIA upon request.
Sample 1
CONDUCT OF THE RESEARCH PROJECT. The Collaborator [or the Parties, if both collaborate] shall use all reasonable endeavours to carry out the Research Project to a high standard and in accordance with the terms of this Agreement. The Collaborator [or the Parties, if both collaborate] shall be responsible for obtaining all necessary ethical, administrative and governmental approvals required to conduct the Research Project as set out in Item 1 of Schedule 2. The Collaborator shall supply all personnel, equipment, materials and other things necessary to carry out its obligations in the Research Project excepting only those items expressed in Item 4 of Schedule 2 which are to be supplied by Barwon Health.
Sample 1
CONDUCT OF THE RESEARCH PROJECT. Collaborator [or the Parties, if both collaborate] shall use all reasonable endeavours to carry out the Research Project to a high standard. Collaborator [or the Parties, if both collaborate shall be responsible for obtaining all necessary ethical, administrative and governmental approvals required to conduct the Research Project as set out in Item 1 of Schedule 2. Collaborator [or the Parties, if both collaborate shall supply all personnel, equipment, materials and other things necessary to perform the Research Project excepting only those items expressed in Item 4 of Schedule 2 to be supplied by The Institution. The Institution shall co-operate with Collaborator and shall not interfere with or obstruct the proper performance of the Research Project.
Sample 1
CONDUCT OF THE RESEARCH PROJECT. Collaborator [or the Parties, if both collaborate] shall use all reasonable endeavours to carry out the Research Project to a high standard. Collaborator [or the Parties, if both collaborate shall be responsible for obtaining all necessary ethical, administrative and governmental approvals required to conduct the Research Project as set out in Item 1 of Schedule 2. Collaborator [or the Parties, if both collaborate shall supply all personnel, equipment, materials and other things necessary to perform the Research Project excepting only those items expressed in Item 4 of Schedule 2 to be supplied by Western Health. Western Health shall co-operate with Collaborator and shall not interfere with or obstruct the proper performance of the Research Project.
Sample 1
AutoNDA by SimpleDocs
CONDUCT OF THE RESEARCH PROJECT. 3.1 The parties shall use all reasonable endeavours to carry out the Research Project to a high standard. 3.2 The Collaborator shall supply the Deliverables to Austin Health on or before, in respect of each Deliverable, the date specified for delivery in Item 5 of Schedule 2. 3.3 Austin Health and the Collaborator shall be responsible for obtaining all necessary ethical, administrative and governmental approvals required to conduct the Research Project as set out in Item 1 of Schedule 2. 3.4 Austin Health and the Collaborator shall supply all personnel, equipment, materials and other things necessary to perform the Research Project as expressed in Item 3 of Schedule 2.
Sample 1
CONDUCT OF THE RESEARCH PROJECT. The Company hereby agrees to devote such resources and effort as is reasonably necessary to (i) conduct the Research Project in accordance with Appendix A and each Quarterly Research Project Work Plan (as defined in Section 3(c)(i) of this Agreement) and (ii) to complete the Quarterly Research Project Activities described in each Quarterly Research Project Work Plan during the Quarterly Research Project Period for such Quarterly Research Project Work Plan. If at any time the Company makes a good faith determination that (A) the Research Project cannot be conducted substantially in accordance with Appendix A or the Research Project Estimated Schedule and Budget; (B) any Phase of the Research cannot be substantially completed within the time frame set forth in Research Project Estimated Schedule and Budget for such Phase; (C) the Quarterly Research Project Activities described in a Quarterly Research Project Work Plan cannot be substantially completed within the Quarterly Research Project Period for such Quarterly Research Project Work Plan; or (D) the continued conduct of the Research Project in accordance with Appendix A is unlikely to yield scientifically valid or useful results, the Company shall promptly give notice (a “Change of Circumstances Notice”) to the Foundation.
Sample 1

Related to CONDUCT OF THE RESEARCH PROJECT

  • Research Project The findings of any research project, which would change the provisions of this Agreement will not be implemented until such changes are negotiated and agreed to by the parties.

  • Conduct of the Study 3.1 Syndax shall act as the sponsor of the Study and shall hold the IND relating to the Study. Merck acknowledges that Syndax intends to file a separate IND covering the clinical evaluation of the Syndax Compound to treat melanoma and lung-related indications and to perform the Study under such IND. This separate IND will not be a combination IND. If a Regulatory Authority requests a separate combination IND for the Study the Parties will meet and mutually agree on an approach to address such requirement. 3.2 Syndax shall ensure that the Study is performed in accordance with this Agreement, the Protocol and all Applicable Law, including GCP. 3.3 Syndax shall ensure that all directions from any Regulatory Authority and/or ethics committee with jurisdiction over the Study are followed. Further, Syndax shall ensure that all necessary Regulatory Approvals from any Regulatory Authority and/or ethics committee with jurisdiction over the Study are obtained prior to initiating performance of the Study. Syndax shall participate in and lead all discussions with any Regulatory Authority regarding the Study, provided, however, that Merck shall have the right (but no obligation) to participate in any discussions with a Regulatory Authority regarding matters related to the Merck Compound. Notwithstanding anything to the contrary in this Agreement, neither Party shall have any right to access the other Party’s CMC data with respect to its Compound. Merck will authorize FDA and other applicable Regulatory Authorities to cross-reference the appropriate Merck Compound CTA to provide data access to Syndax sufficient to support conduct of the Study, which authorization will take the form of a cross-reference letter or similar communication to the applicable Regulatory Authority to effectuate a “right of reference” (as defined in US FDA 21 CFR 314.3(b)), or similar “right of reference” as defined in applicable regulations in the relevant part of the Territory. If an appropriate Merck Compound CTA is not available in a given country, Merck will file its CMC data as appropriate and grant right of reference to such CMC data; provided, however, that Syndax shall have no right to directly access the CMC data. 3.4 Syndax shall maintain reports and all related documentation relating to the Study in good scientific manner and in compliance with Applicable Law. Each Party shall provide to the other all Study information and documentation (excluding information and documentation relating to the Sample Testing other than the Sample Testing Results themselves) reasonably requested by such other Party to enable it to (i) comply with any of its legal and regulatory obligations, or any request by any Regulatory Authority, in each case, to the extent related to the Study or such Party’s Compound, or (ii) conduct the Sample Testing. 3.5 Each Party shall provide to the other Party copies of all Clinical Data, in electronic form or other mutually agreeable alternate form, and on the timelines specified in the Data Sharing and Sample Testing Schedule (if applicable) or upon mutually agreeable timelines. Syndax shall ensure that all patient authorizations and consents required under HIPAA, the EU Data Protection Directive, GCP or any other Applicable Law in connection with the Study permit such sharing of Clinical Data with Merck. 3.6 Syndax shall provide Samples to Merck as specified in the Protocol or as agreed to by the Joint Development Committee. Each Party shall use the Samples only for the Sample Testing and each Party shall be responsible for conducting the Sample Testing related to its own Compound. Merck shall own all data arising from the Sample Testing conducted by or on behalf of Merck. Merck shall provide to Syndax the Sample Testing Results for the Sample Testing conducted by or on behalf of Merck, in electronic form or other mutually agreeable alternate form, and on the timelines specified in the Data Sharing and Sample Testing Schedule or other mutually agreed timelines. Likewise, Syndax shall own all data arising from the Sample Testing conducted by or on behalf of Syndax. Syndax shall provide to Merck the Sample Testing Results for the Sample Testing conducted by or on behalf of Syndax, in electronic form or other mutually agreeable alternate form, and on the timelines specified in the Data Sharing and Sample Testing Schedule or other mutually agreed timelines. Except to the extent otherwise agreed in a writing signed by authorized representatives of each Party, each Party shall use the other Party’s Sample Testing Results only for the purposes of ***. Further, Merck covenants not to ***, and Syndax covenants not ***; provided, however, that the foregoing shall not prevent either Party from ***. 3.7 All Clinical Data, including raw data and results, generated under this Agreement shall be jointly owned by Syndax and Merck. It is understood and acknowledged by the Parties that positive Clinical Data could be used to obtain label changes for the Compounds. In such event, the Parties will enter into good faith negotiations to determine a regulatory submission strategy for the Compounds, and cost structure of the next part of the Study and/or future study(ies) that may be needed for regulatory submission for the Compounds. Merck covenants not to ***, and Syndax covenants not to ***; provided, however, that the foregoing shall not prevent either Party from ***.

  • Development of the Project 4.1 TSP's obligations in development of the Project: a. for procuring and maintaining in full force and effect all Consents, Clearances and Permits, required in accordance with Law for development of the Project; b. for financing, constructing, owning and commissioning each of the Element of the Project for the scope of work set out in Schedule 1 of this Agreement in accordance with: i. the Electricity Act and the Rules made thereof; ii. the Grid Code; iii. the CEA Regulations applicable, and as amended from time to time, for Transmission Lines and sub-stations: • the Central Electricity Authority (Technical Standards for Connectivity to the Grid) Regulations, 2007; • Central Electricity Authority (Technical Standards for construction of Electrical Plants and Electric Lines) Regulation, 2010; • Central Electricity Authority (Grid Standard) Regulations, 2010; • Central Electricity Authority (Safety requirements for construction, operation and maintenance of Electrical Plants and Electrical Lines) Regulation, 2011; • Central Electricity Authority (Measures relating to Safety and Electricity Supply) Regulation, 2010; • Central Electricity Authority (Technical Standards for Communication System in Power System Operation) Regulations, 2020. iv. Safety/ security Guidelines laid down by the Government; v. Prudent Utility Practices, relevant Indian Standards and the Law; not later than the Scheduled COD as per Schedule 2 of this Agreement; c. for entering into a Connection Agreement with the concerned parties in accordance with the Grid Code. d. for owning the Project throughout the term of this Agreement free and clear of any encumbrances except those expressly permitted under Article 15 of this Agreement; e. to co-ordinate and liaise with concerned agencies and provide on a timely basis relevant information with regard to the specifications of the Project that may be required for interconnecting the Project with the Interconnection Facilities; f. for providing all assistance to the Arbitrators as they may require for the performance of their duties and responsibilities; g. to provide to the Nodal Agency and CEA, on a monthly basis, progress reports with regard to the Project and its execution (in accordance with prescribed form) to enable the CEA to monitor and co-ordinate the development of the Project matching with the Interconnection Facilities; h. to comply with Ministry of Power order no. 25-11/6/2018 – PG dated 02.07.2020 as well as other Guidelines issued by Govt. of India pertaining to this; i. to procure the products associated with the Transmission System as per provisions of Public Procurement (Preference to Make in India) orders issued by Ministry of Power vide orders No. 11/5/2018 - Coord. dated 28.07.2020 for transmission sector, as amended from time to time read with Department for Promotion of Industry and Internal Trade (DPIIT) orders in this regard (Procuring Entity as defined in above orders shall deemed to have included Selected Bidder and/ or TSP). Also, to comply with Department of Expenditure, Ministry of Finance vide Order (Public Procurement No 1) bearing File No. 6/18/2019- PPD dated 23.07.2020, Order (Public Procurement No 2) bearing File No. 6/18/2019-PPD dated 23.07.2020 and Order (Public Procurement No. 3) bearing File No. 6/18/2019-PPD, dated 24.07.2020, as amended from time to time, regarding public procurement from a bidder of a country, which shares land border with India; j. to submit to Nodal Agency information in the prescribed format [To be devised by Nodal Agency] for ensuring compliance to Article 4.1 i) above. k. to comply with all its obligations undertaken in this Agreement. 4.2 Roles of the Nodal Agency in implementation of the Project: 4.2.1 Subject to the terms and conditions of this Agreement, the Nodal Agency shall be the holder and administrator of this Agreement and shall inter alia: a. appoint an Independent Engineer within 90 days of the Effective Date b. provide letters of recommendation to the concerned Indian Governmental Instrumentality, as may be requested by the TSP from time to time, for obtaining the Consents, Clearances and Permits required for the Project; c. coordinate among TSP and upstream/downstream entities in respect of Interconnection Facilities; and d. monitor the implementation of the Agreement and take appropriate action for breach thereof including revocation of guarantees, cancellation of Agreement, blacklisting etc e. provide all assistance to the Arbitrators as required for the performance of their duties and responsibilities; and f. perform any other responsibility (ies) as specified in this Agreement.

  • Research Program The term “Research Program” shall mean the research program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto.

  • Development of the Property Except as modified by this Agreement, the Development and the Property will be developed in accordance with all applicable local, state, and federal regulations, including but not limited to the City’s ordinances and the zoning regulations applicable to the Property, and such amendments to City ordinances and regulations that that may be applied to the Development and the Property under Chapter 245, Texas Local Government Code, and good engineering practices (the “Applicable Regulations”). If there is a conflict between the Applicable Regulations and the Development Standards, the Development Standards shall control.

  • Conduct of Research The Parties shall use Diligent Efforts to conduct their respective tasks, as assigned under the Research Plan, throughout the Mode of Action Program and shall conduct the Mode of Action Program in good scientific manner, and in compliance in all material respects with the requirements of applicable laws, rules and regulations and all applicable good laboratory practices to attempt to achieve their objectives efficiently and expeditiously.

  • Conduct of the Parties The parties will not engage in behaviour that is, or may reasonably be considered to be intimidating, bullying, or harassing or commit any act or behaviour which is offensive or abusive in connection with this Agreement.

  • Development Work The Support Standards do not include development work either (i) on software not licensed from CentralSquare or (ii) development work for enhancements or features that are outside the documented functionality of the Solutions, except such work as may be specifically purchased and outlined in Exhibit 1. CentralSquare retains all Intellectual Property Rights in development work performed and Customer may request consulting and development work from CentralSquare as a separate billable service.

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Research Matters By entering into this Agreement, the Placement Agent does not provide any promise, either explicitly or implicitly, of favorable or continued research coverage of the Company and the Company hereby acknowledges and agrees that the Placement Agent’s selection as a placement agent for the Offering was in no way conditioned, explicitly or implicitly, on the Placement Agent providing favorable or any research coverage of the Company. In accordance with FINRA Rule 2711(e), the parties acknowledge and agree that the Placement Agent has not directly or indirectly offered favorable research, a specific rating or a specific price target, or threatened to change research, a rating or a price target, to the Company or inducement for the receipt of business or compensation.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!